Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).
Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).
It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
Post‐surgical chemotherapy leads to lower disease Free Survival compared with surgery alone (high certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).